NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Timothy Perren
University of Leeds - Leeds / United Kingdom
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 1226863
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Timothy Perren's MOST POPULAR ARTICLES
1-)
A phase 3 trial of bevacizumab in ovarian cancerTJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ...New England Journal of Medicine 365 (26), 2484-2496, 201122142011
2-)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialS Kehoe, J Hook, M Nankivell, GC Jayson, H Kitchener, T Lopes, ...The Lancet 386 (9990), 249-257, 201511242015
3-)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialAM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...The Lancet Oncology 16 (8), 928-936, 20157172015
4-)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialTM Suter, M Procter, DJ van Veldhuisen, M Muscholl, J Bergh, ...Journal of clinical oncology 25 (25), 3859-3865, 20077002007
5-)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialM Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...The lancet oncology 18 (12), 1688-1700, 20176612017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept